Adrian Newman-Tancredi, PhD, DSc
Co-Founder and Chief Scientific Officer
Dr. Newman-Tancredi has over 20 years' experience of neuroscience research and drug discovery. Prior to joining Neurolixis, he was Director of Neurobiology and Project Manager at Pierre Fabre Laboratories where he led multi-disciplinary programs that identified and characterized novel antipsychotics, antidepressants and analgesics. Prior to Pierre Fabre, Dr. Newman-Tancredi led a molecular pharmacology group at the Servier Research Institute where he was responsible for screening of NCEs and investigating signal transduction mechanisms of monoamine receptors. Drugs characterized in the course of Dr. Newman-Tancredi's work include milnacipran (Savella ®), piribedil (Trivastal ®), agomelatine (Valdoxan ®), levomilnacipran (Fetzima ®) and befiradol (NLX-112). In addition, Dr. Newman-Tancredi managed the program that led to the discovery of the serotonergic "biased agonist", F15599 (NLX-101).
Dr. Newman-Tancredi has extensive experience of team management, integrating medicinal chemistry, pharmacology, early ADMET and preclinical development, and collaborating with academic researchers. He has published over 150 articles in peer-reviewed journals, co-authored patents on NCEs and given presentations to a wide variety of audiences. He serves on the Editorial Board of the International Journal of Neuropsychopharmacology, as European Councillor of the International Society for Serotonin Research and as an independent drug discovery consultant (www.neuroact.com). Dr. Newman-Tancredi received his BSc with honours in Biochemistry, followed by a PhD and a DSc in neuropharmacology from the University of Kent at Canterbury, U.K. He is bi-national (anglo-italian) and tri-lingual (English, French, Italian).